Needham & Company increased its target price and gave a buy rating for MoonLake Immunotherapeutics.
1 report, 1 independent
Updated Jul 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Needham & Company increased its target price and gave a buy rating for MoonLake Immunotherapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
Related events
- Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
- Citigroup reissued a market outperform rating and Needham lifted its target price for Alkami Technology Inc.
- Needham & Company cut its target price and set a buy rating for Applied Optoelectronics, while Raymond James Financial reiterated an outperform rating. MarketBeat provided consensus data.
- Needham & Company cut its price target and set a buy rating for Endava, while CLSA also set a $5.00 price objective.
Coverage
Newest first; wire copies grouped- themarketsdaily.comRice Hall James & Associates LLC Buys 40,301 Shares of MoonLake Immunotherapeutics $MLTX